AB

Bibliografia publikacji pracowników
Państwowej Szkoły Wyższej w Białej Podlaskiej

Baza tworzona przez Bibliotekę Akademii Bialskiej im. Jana Pawła II.


Zapytanie: ARDS
Liczba odnalezionych rekordów: 2



Przejście do opcji zmiany formatu | Wyświetl/ukryj etykiety | Wyświetlenie wyników w wersji do druku | Pobranie pliku do edytora | Nowe wyszukiwanie
1/2
Nr opisu: 0000041755
Autorzy: Oleksandr Oliynyk, Wojciech Barg, Anna Ślifirczyk, Yanina Oliynyk, Vitaliy Gurianov, Marta Rorat.
Tytuł pracy: Efficacy of Tocilizumab Therapy in Different Subtypes of COVID-19 Cytokine Storm Syndrome
Tytuł czasopisma:
Szczegóły: 2021, Vol. 13, issue 6, article number 1067
p-ISSN: 1999-4915
Charakterystyka formalna: artykuł w czasopiśmie zagranicznym
Charakterystyka merytoryczna: artykuł oryginalny naukowy
Charakterystyka wg MNiSW: artykuł w czasopiśmie z IF (wykaz MEiN)
Język publikacji: ENG
Wskaźnik Impact Factor ISI: 5.818
Punktacja ministerstwa: 100.000
Słowa kluczowe ang.: monoclonal antibodies ; ARDS ; cytokine strom syndrome ; inflammation
Inne bazy podające opis:
  • Scopus

    https://www.mdpi.com/1999-4915/13/6/1067
    DOI: 10.3390/v13061067
    Streszczenie: Background: Cytokine storm in COVID-19 is heterogenous. There are at least three subtypes: cytokine release syndrome (CRS), macrophage activation syndrome (MAS), and sepsis. Methods: A retrospective study comprising 276 patients with SARS-CoV-2 pneumonia. All patients were tested for ferritin, interleukin-6, D-Dimer, fibrinogen, calcitonin, and C-reactive protein. According to the diagnostic criteria, three groups of patients with different subtypes of cytokine storm syndrome were identified: MAS, CRS or sepsis. In the MAS and CRS groups, treatment results were assessed depending on whether or not tocilizumab was used. Results: MAS was diagnosed in 9.1% of the patients examined, CRS in 81.8%, and sepsis in 9.1%. Median serum ferritin in patients with MAS was significantly higher (5894 vs. 984 vs. 957 ng/mL, p < 0.001) than in those with CRS or sepsis. Hypofibrinogenemia and pancytopenia were also observed in MAS patients. In CRS patients, a higher mortality rate was observed among those who received tocilizumab, 21 vs. 10 patients (p = 0.043), RR = 2.1 (95% CI 1.0-4.3). In MAS patients, tocilizumab decreased the mortality, 13 vs. 6 patients (p = 0.013), RR = 0.50 (95% CI 0.25-0.99). Conclusions: Tocilizumab therapy in patients with COVID-19 and CRS was associated with increased mortality, while in MAS patients, it contributed to reduced mortality.

    2/2
    Nr opisu: 0000041175
    Autorzy: Oleksandr V. Oliynyk, Marta Rorat, Wojciech Barg.
    Tytuł pracy: Oxygen metabolism markers as predictors of mortality in severe COVID-19
    Tytuł czasopisma:
    Szczegóły: 2021, Vol. 103, p. 452--456
    p-ISSN: 1201-9712
    e-ISSN: 1878-3511
    Charakterystyka formalna: artykuł w czasopiśmie zagranicznym
    Charakterystyka merytoryczna: artykuł oryginalny naukowy
    Charakterystyka wg MNiSW: artykuł w czasopiśmie z IF (wykaz MEiN)
    Język publikacji: ENG
    Wskaźnik Impact Factor ISI: 12.074
    Punktacja ministerstwa: 100.000
    Słowa kluczowe ang.: COVID-19 ; ARDS ; oxygen metabolism ; determinants of mortality ; respiratory failure
    https://www.sciencedirect.com/science/article/pii/S1201971220325352
    DOI: 10.1016/j.ijid.2020.12.012
    Streszczenie: Objective: To investigate the use of oxygen metabolism markers as predictors of mortality in patients withsevere coronavirus disease 2019 (COVID-19). Methods: A retrospective analysis was undertaken to compare the medical records of patients with severeCOVID-19 (53 deceased patients and 50 survivors). The survivors were selected from 222 records using arandom number generator. In addition, 28 individuals who considered themselves to be healthy and whohad no history of serious illness were included in the study for comparison. Oxygen saturation in arterialblood, oxygen saturation in central venous blood (ScvO2), arterial partial pressure of oxygen (PaO2),respiratory index (PaO2/fraction of inspired oxygen), oxygen delivery, oxygen consumption (VO2) andoxygen extraction (O2ER) were compared in all participants. The optimal cut-off point for each oxygenmetabolism marker in the prediction of mortality was determined based on the maximum value of theYouden Index in receiver operating characteristic curve analysis. Results: Significant differences in all studied oxygen metabolism markers were found between survivorscompared with deceased patients (p < 0.001). ScvO2, VO2and O2ER [area under curve (AUC) 1.0] were thestrongest predictors of mortality, and PaO2was the weakest predictor of mortality (AUC 0.81). ScvO2<29%, VO2>124.6 ml/min and O2ER >30.2% were identified as predictors of mortality in patients withCOVID-19.Conclusion: ScvO2, VO2 and O2ER are good predictors of mortality in critically ill patients with COVID-19.

      Wyświetl ponownie stosując format:
    • Wyświetl/ukryj etykiety | Wyświetlenie wyników w wersji do druku | Pobranie pliku do edytora | Nowe wyszukiwanie | Biblioteka AB